Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.

Authors

Dean F. Bajorin

Memorial Sloan-Kettering Cancer Center, New York, NY

Dean F. Bajorin , Padmanee Sharma , Seth P. Lerner , Robert Brownell Sims , Amanda Sanders , Todd DeVries , Nadeem A. Sheikh , Leonard G. Gomella

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence.

First Author: Dean F. Bajorin

insert_chart_outlined

Poster

2014 Genitourinary Cancers Symposium

bookmark_border

NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer.

First Author: Dean F. Bajorin

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Preliminary HER2 expression data from NeuACT, the phase II randomized, open-label trial of DN24-02 in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.

First Author: Michael F. Press

insert_chart_outlined

Poster

2013 Genitourinary Cancers Symposium

bookmark_border

HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2.

First Author: Michael F. Press